Cardio Diagnostics Holdings, Inc.

NasdaqCM CDIO

Cardio Diagnostics Holdings, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2024: 22,167,026

Cardio Diagnostics Holdings, Inc. Shares (Diluted, Weighted) is 22,167,026 for the Trailing 12 Months (TTM) ending September 30, 2024, a 115.17% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Cardio Diagnostics Holdings, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2023 was 10,302,014, a 12.38% change year over year.
Cardio Diagnostics Holdings, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2022 was 9,167,307.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqCM: CDIO

Cardio Diagnostics Holdings, Inc.

CEO	Dr. Meeshanthini V. Dogan Ph.D.
IPO Date	Jan. 14, 2022
Location	United States
Headquarters	400 N Aberdeen St
Employees	7
Sector	Health Care
Industries Clinical Trials Biotechnology

Description

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.

Key trends

Past 5 years